Insmed, Inc. (NASDAQ:INSM) Stock Has Consensus Target Price of $201.87 According to Analysts

Key Points

• Analysts remain bullish on Insmed: Twenty-two of 25 covering brokerages rate the stock a buy, with two strong-buy ratings and one sell rating. The consensus 12-month price target is $201.87, well above the reported $121.55 share price.
• Insmed reported quarterly EPS of -$0.06, beating the $0.67 loss analysts expected, while revenue rose 296.1% year over year to $425.49 million, exceeding estimates of $395.50 million.
• Insiders sold approximately $36.3 million of stock over the past three months, including significant sales by the CEO and COO, while several major institutional investors increased their positions.

Insmed, Inc. (NASDAQ:INSM - Get Free Report) has been assigned an average rating of "Buy" from the twenty-five brokerages that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, twenty-two have issued a buy rating and two have issued a strong buy rating on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $201.87.

A number of research analysts have commented on the stock. Jefferies Financial Group restated a "buy" rating and set a $175.00 price target on shares of Insmed in a research note on Thursday, August 6th. Evercore reissued an "outperform" rating and issued a $170.00 target price on shares of Insmed in a report on Friday, August 7th. UBS Group restated a "buy" rating and set a $172.00 target price on shares of Insmed in a research report on Friday, August 7th. Royal Bank Of Canada cut their target price on Insmed from $205.00 to $195.00 and set an "outperform" rating for the company in a research report on Friday, June 5th. Finally, BMO Capital Markets began coverage on Insmed in a research report on Monday, July 20th. They issued an "outperform" rating and a $192.00 price target on the stock.

Insmed Trading Up 2.7%

Shares of Insmed stock opened at $121.55 on Friday. The firm has a market capitalization of $26.54 billion, a PE ratio of -29.57 and a beta of 0.82. The company has a debt-to-equity ratio of 0.74, a current ratio of 3.72 and a quick ratio of 3.40. The company's fifty day moving average price is $119.40 and its two-hundred day moving average price is $122.31. Insmed has a 52-week low of $90.39 and a 52-week high of $212.75.

Insmed (NASDAQ:INSM - Get Free Report) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.67) by $0.61. The business had revenue of $425.49 million for the quarter, compared to analyst estimates of $395.50 million. Insmed had a negative net margin of 76.94% and a negative return on equity of 123.94%. The firm's revenue was up 296.1% on a year-over-year basis. During the same period in the previous year, the business earned ($1.70) EPS. On average, analysts expect that Insmed will post -1.84 EPS for the current year.

Insider Buying and Selling at Insmed

In other news, CEO William Lewis sold 10,699 shares of the business's stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $117.40, for a total value of $1,256,062.60. Following the sale, the chief executive officer owned 259,058 shares in the company, valued at approximately $30,413,409.20. The trade was a 3.97% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Roger Adsett sold 239,850 shares of the company's stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $133.27, for a total transaction of $31,964,809.50. Following the completion of the sale, the chief operating officer directly owned 98,744 shares in the company, valued at approximately $13,159,612.88. The trade was a 70.84% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 275,549 shares of company stock valued at $36,320,872. 2.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Insmed

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its stake in shares of Insmed by 14.4% in the fourth quarter. Geode Capital Management LLC now owns 4,299,052 shares of the biopharmaceutical company's stock valued at $751,936,000 after acquiring an additional 539,625 shares during the last quarter. Norges Bank bought a new stake in Insmed during the 4th quarter worth approximately $506,625,000. Franklin Resources Inc. increased its holdings in Insmed by 28.8% during the 4th quarter. Franklin Resources Inc. now owns 2,755,536 shares of the biopharmaceutical company's stock valued at $479,573,000 after purchasing an additional 615,811 shares in the last quarter. Sei Investments Co. increased its holdings in Insmed by 56.8% during the 1st quarter. Sei Investments Co. now owns 1,395,794 shares of the biopharmaceutical company's stock valued at $228,239,000 after purchasing an additional 505,624 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its position in Insmed by 22.1% in the 4th quarter. Bank of New York Mellon Corp now owns 1,390,042 shares of the biopharmaceutical company's stock valued at $241,923,000 after purchasing an additional 251,141 shares during the last quarter.

Insmed Company Profile

Insmed Incorporated NASDAQ: INSM is a global biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases. The company's work centers on areas of significant unmet medical need, including pulmonary and infectious diseases, as well as other specialty conditions.

Insmed's primary commercial product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled antibacterial therapy approved in the United States for adults with refractory Mycobacterium avium complex lung disease as part of a combination antibacterial regimen.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.